Overview

A Study of MD-120 in Patients With Depression

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.

Phase:

Phase 3

Details

Lead Sponsor:

Mochida Pharmaceutical Company, Ltd.

Collaborator:

Pfizer

Treatments:

Desvenlafaxine Succinate